Studies found that the riboflavin (vitamin B2) responsive multiple acyl-CoA dehydrogenase deficiencies (RR-MADD) caused by ETFDH mutation and the clinical symptoms of patients treated with riboflavin can be significantly improved [13,14]. The gene discussed is ETFDH; the disease is multiple acyl-CoA dehydrogenase deficiency.